Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3626 results
Ablynx signs cancer immunotherapy collaboration, licensing agreement with Merck
04 February 2014 | By PBR Staff Writer
Belgian biopharmaceutical firm Ablynx has entered into a second research collaboration and licensing agreement with a subsidiary of Merck.
Drug Research > Drug Discovery & Development > News
Selcia, University of Edinburgh enter GBP2.5m project for new fatal disease drug
04 February 2014 | By PBR Staff Writer
UK-based life sciences contract research organization (CRO) Selcia and scientists from the University of Edinburgh have jointly launched a GBP2.5m project to develop new drugs for the treatment of sleeping sickness.
Drug Research > Drug Discovery & Development > News
EdisonPharma enters into drug development agreement with Dainippon Sumitomo
03 February 2014 | By PBR Staff Writer
US-based Edison Pharmaceuticals has entered into agreement with Japanese pharmaceutical firm Dainippon Sumitomo Pharma (DSP) worth $4.295bn for the development of new drugs targeting cellular energy metabolism.
Drug Research > Drug Discovery & Development > News
Regado Biosciences announces $20m private placement
03 February 2014
Regado Biosciences, a biopharmaceutical company focused on the late-stage clinical development of its actively controllable antithrombotic drug system, REG1, has entered into a definitive agreement to sell $20m of its common stock in a private placement to new and existing investors.
Drug Research > Drug Discovery & Development > News
FOB Synthesis enters into antibiotic development agreement with AstraZeneca
28 January 2014 | By PBR Staff Writer
US-based FOB Synthesis and AstraZeneca have entered into a research and development option and license agreement for the development of a novel antibiotic for the treatment of drug-resistant bacterial infections.
Drug Research > Drug Discovery & Development > News
NIBIO, Aeras, Create Vaccine sign agreement to develop new TB vaccines
28 January 2014 | By PBR Staff Writer
The National Institute of Biomedical Innovation of Japan (NIBIO), Aeras, and Create Vaccine have signed a collaboration agreement for the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO’s human parainfluenza type‐2 (rhPIV2) vector technology.
Drug Research > Drug Discovery & Development > News
Teva and Active Biotech remain committed for development of Nerventra for multiple sclerosis
27 January 2014
Teva Pharmaceutical Industries and Active Biotech have announced that both companies remain committed to the Nerventra (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Drug Research > Drug Discovery & Development > News
Celsion initiates development program for glioblastoma brain tumors with thermodox and HIFU
23 January 2014
Celsion, an oncology drug development company, has announced that the company is formalizing a program to pursue the development of ThermoDox to investigate applications for treating brain cancer tumors, notably Glioblastoma Multiforme or GBM.
Drug Research > Drug Discovery & Development > News
Actavis confirms court upholds Lo Loestrin Fe patent
21 January 2014
Actavis has confirmed that the US District Court for the District of New Jersey found US Patent No 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals and Amneal Pharmaceuticals abbreviated new drug applications (ANDAs) for generic versions of Actavis' Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets).
Drug Research > Drug Discovery & Development > News
Sanofi, Fraunhofer create new natural product center of excellence
17 January 2014 | By PBR Staff Writer
French pharmaceutical firm Sanofi and Germany-based Fraunhofer-Gesellschaft have formed a natural product center of excellence to speed up the discovery and development of new therapies to treat infectious diseases.
Drug Research > Drug Discovery & Development > News
Amgen, MGH, Broad Institute to discover new drugs to treat inflammatory bowel disease
16 January 2014 | By PBR Staff Writer
Amgen (AMGN), Massachusetts General Hospital (MGH) and the Broad Institute have entered inot a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD).
Drug Research > Drug Discovery & Development > News
Cellceutix provides updates on clinical trials and developments of Its anti-cancer, anti-psoriasis, and antibiotic compounds
16 January 2014
Cellceutix, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today provides shareholders with an update on the current status of the Company's compounds in development.
Drug Research > Drug Discovery & Development > News
Galena Biopharma, Dr. Reddy's partner for NeuVax in India
15 January 2014 | By PBR Staff Writer
Galena Biopharma and Dr. Reddy's Laboratories have entered into a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India.
Drug Research > Drug Discovery & Development > News
Amarantus in-licenses Levadopa-induced dyskinesia phase 2b-ready Eltoprazine from PGI drug discovery
15 January 2014
Amarantus Bioscience Holdings, a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, announced that it has completed the in-licensure of Eltoprazine from PGI Drug Discovery LLC.
Drug Research > Drug Discovery & Development > News
Portola signs second clinical collaboration agreement with Bristol-Myers Squibb and Pfizer
14 January 2014
Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Bristol-Myers Squibb Company and Pfizer to study Portola's investigational Factor Xa inhibitor reversal agent, andexanet alfa (PRT4445), with the oral Factor Xa inhibitor Eliquis (apixaban).
Drug Research > Drug Discovery & Development > News
61-75 of 3626 results